Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Advances in the Use of Real-World Evidence for Medical Devices: An Update From the National Evaluation System for Health Technology.

Fleurence RL, Shuren J.

Clin Pharmacol Ther. 2019 Jul;106(1):30-33. doi: 10.1002/cpt.1380. Epub 2019 Mar 19. No abstract available.

2.

The Future of Registries in the Era of Real-world Evidence for Medical Devices.

Fleurence RL, Blake K, Shuren J.

JAMA Cardiol. 2019 Feb 20. doi: 10.1001/jamacardio.2018.4933. [Epub ahead of print] No abstract available.

PMID:
30785595
3.

Transforming Evidence Generation to Support Health and Health Care Decisions.

Califf RM, Robb MA, Bindman AB, Briggs JP, Collins FS, Conway PH, Coster TS, Cunningham FE, De Lew N, DeSalvo KB, Dymek C, Dzau VJ, Fleurence RL, Frank RG, Gaziano JM, Kaufmann P, Lauer M, Marks PW, McGinnis JM, Richards C, Selby JV, Shulkin DJ, Shuren J, Slavitt AM, Smith SR, Washington BV, White PJ, Woodcock J, Woodson J, Sherman RE.

N Engl J Med. 2016 Dec 15;375(24):2395-2400. No abstract available.

4.

The ADAPTABLE Trial and PCORnet: Shining Light on a New Research Paradigm.

Hernandez AF, Fleurence RL, Rothman RL.

Ann Intern Med. 2015 Oct 20;163(8):635-6. doi: 10.7326/M15-1460. Epub 2015 Aug 25. No abstract available.

PMID:
26301537
5.

The Patient-centered Outcomes Research Institute's Role in Advancing Methods for Patient-centered Outcomes Research.

Fleurence R, Whicher D, Dunham K, Gerson J, Newhouse R, Luce B.

Med Care. 2015 Jan;53(1):2-8. doi: 10.1097/MLR.0000000000000244. No abstract available.

6.

Evidence-based prescribing: combining network meta-analysis with multicriteria decision analysis to choose among multiple drugs.

Naci H, van Valkenhoef G, Higgins JP, Fleurence R, Ades AE.

Circ Cardiovasc Qual Outcomes. 2014 Sep;7(5):787-92. doi: 10.1161/CIRCOUTCOMES.114.000825. Epub 2014 Aug 5. Review. No abstract available.

PMID:
25097214
7.

A systematic review of approaches for engaging patients for research on rare diseases.

Forsythe LP, Szydlowski V, Murad MH, Ip S, Wang Z, Elraiyah TA, Fleurence R, Hickam DH.

J Gen Intern Med. 2014 Aug;29 Suppl 3:S788-800. doi: 10.1007/s11606-014-2895-9. Review.

8.

Engaging patients and stakeholders in research proposal review: the patient-centered outcomes research institute.

Fleurence RL, Forsythe LP, Lauer M, Rotter J, Ioannidis JP, Beal A, Frank L, Selby JV.

Ann Intern Med. 2014 Jul 15;161(2):122-30. doi: 10.7326/M13-2412.

PMID:
25023251
9.

Patient-powered research networks aim to improve patient care and health research.

Fleurence RL, Beal AC, Sheridan SE, Johnson LB, Selby JV.

Health Aff (Millwood). 2014 Jul;33(7):1212-9. doi: 10.1377/hlthaff.2014.0113.

PMID:
25006148
10.

Launching PCORnet, a national patient-centered clinical research network.

Fleurence RL, Curtis LH, Califf RM, Platt R, Selby JV, Brown JS.

J Am Med Inform Assoc. 2014 Jul-Aug;21(4):578-82. doi: 10.1136/amiajnl-2014-002747. Epub 2014 May 12.

11.

Patient-powered research networks: building capacity for conducting patient-centered clinical outcomes research.

PCORnet PPRN Consortium, Daugherty SE, Wahba S, Fleurence R.

J Am Med Inform Assoc. 2014 Jul-Aug;21(4):583-6. doi: 10.1136/amiajnl-2014-002758. Epub 2014 May 12.

12.

Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study.

Connor JT, Luce BR, Broglio KR, Ishak KJ, Mullins CD, Vanness DJ, Fleurence R, Saunders E, Davis BR.

Clin Trials. 2013 Oct;10(5):807-27. doi: 10.1177/1740774513497293. Epub 2013 Aug 27.

13.

Toward a science of research prioritization? The use of value of information by multidisciplinary stakeholder groups.

Fleurence RL, Meltzer DO.

Med Decis Making. 2013 May;33(4):460-2. doi: 10.1177/0272989X13486979. No abstract available.

PMID:
23635832
14.

Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials.

Naci H, Brugts JJ, Fleurence R, Ades AE.

Eur J Prev Cardiol. 2013 Aug;20(4):658-70. doi: 10.1177/2047487313483600. Epub 2013 Mar 25. Review.

PMID:
23529608
15.

Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials.

Naci H, Brugts JJ, Fleurence R, Tsoi B, Toor H, Ades AE.

Eur J Prev Cardiol. 2013 Aug;20(4):641-57. doi: 10.1177/2047487313480435. Epub 2013 Feb 27. Review.

PMID:
23447425
16.

Comparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials.

Naci H, Brugts JJ, Fleurence R, Ades AE.

QJM. 2013 Apr;106(4):299-306. doi: 10.1093/qjmed/hct041. Epub 2013 Feb 21.

PMID:
23431221
17.

How the Patient-Centered Outcomes Research Institute is engaging patients and others in shaping its research agenda.

Fleurence R, Selby JV, Odom-Walker K, Hunt G, Meltzer D, Slutsky JR, Yancy C.

Health Aff (Millwood). 2013 Feb;32(2):393-400. doi: 10.1377/hlthaff.2012.1176.

PMID:
23381533
18.

Reviewing hypothetical migraine studies using funding criteria from the Patient-Centered Outcomes Research Institute.

Selby JV, Fleurence R, Lauer M, Schneeweiss S.

Health Aff (Millwood). 2012 Oct;31(10):2193-9. doi: 10.1377/hlthaff.2012.0774.

PMID:
23048096
19.

Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1.

Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, Lee K, Boersma C, Annemans L, Cappelleri JC.

Value Health. 2011 Jun;14(4):417-28. doi: 10.1016/j.jval.2011.04.002.

20.

A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes.

Hutchins V, Zhang B, Fleurence RL, Krishnarajah G, Graham J.

Curr Med Res Opin. 2011 Jun;27(6):1157-68. doi: 10.1185/03007995.2011.570745. Epub 2011 Apr 5. Review.

PMID:
21466277
21.

Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.

Pan F, Peng S, Fleurence R, Linnehan JE, Knopf K, Kim E.

Clin Ther. 2010 Dec;32(14):2444-56. doi: 10.1016/j.clinthera.2010.12.003.

PMID:
21353113
22.

The critical role of observational evidence in comparative effectiveness research.

Fleurence RL, Naci H, Jansen JP.

Health Aff (Millwood). 2010 Oct;29(10):1826-33. doi: 10.1377/hlthaff.2010.0630.

PMID:
20921482
23.

Economic burden of multiple sclerosis: a systematic review of the literature.

Naci H, Fleurence R, Birt J, Duhig A.

Pharmacoeconomics. 2010;28(5):363-79. doi: 10.2165/11532230-000000000-00000. Review.

PMID:
20402540
24.

Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis.

Fleurence RL, Spackman DE, Hollenbeak C.

Pharmacoeconomics. 2010;28(4):295-306. doi: 10.2165/11530530-000000000-00000.

PMID:
20222753
25.

The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature.

Naci H, Fleurence R, Birt J, Duhig A.

J Med Econ. 2010 Mar;13(1):78-89. doi: 10.3111/13696990903543085. Review.

PMID:
20047364
26.

A systematic review of augmentation strategies for patients with major depressive disorder.

Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME.

Psychopharmacol Bull. 2009;42(3):57-90. Review.

PMID:
19752841
27.

Cost and clinical consequence of antibiotic non-adherence in acute exacerbations of chronic bronchitis.

Sorensen SV, Baker T, Fleurence R, Dixon J, Roberts C, Haider S, Hughes D.

Int J Tuberc Lung Dis. 2009 Aug;13(8):945-54. Review.

PMID:
19723373
28.

Economic outcomes associated with atypical antipsychotics in bipolar disorder: a systematic review.

Fleurence RL, Chatterton ML, Dixon JM, Rajagopalan K.

Prim Care Companion J Clin Psychiatry. 2007;9(6):419-28.

29.

The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Fleurence RL, Iglesias CP, Johnson JM.

Pharmacoeconomics. 2007;25(11):913-33. Review.

PMID:
17960951
30.

Review of the economic and quality-of-life burden of cervical human papillomavirus disease.

Fleurence RL, Dixon JM, Milanova TF, Beusterien KM.

Am J Obstet Gynecol. 2007 Mar;196(3):206-12. Review.

PMID:
17346523
31.
32.
33.
34.

Economics of atypical antipsychotics in bipolar disorder: a review of the literature.

Fleurence RL, Dixon JM, Revicki DA.

CNS Drugs. 2006;20(7):591-9. Review.

PMID:
16800717
35.

Cost-effectiveness of pressure-relieving devices for the prevention and treatment of pressure ulcers.

Fleurence RL.

Int J Technol Assess Health Care. 2005 Summer;21(3):334-41.

PMID:
16110713
36.

Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature.

Fleurence RL, Iglesias CP, Torgerson DJ.

Osteoporos Int. 2006 Jan;17(1):29-40. Epub 2005 Jun 25. Review.

PMID:
15981019
37.
38.

Setting priorities for research.

Fleurence RL, Torgerson DJ.

Health Policy. 2004 Jul;69(1):1-10.

PMID:
15484602
39.

Cost-effectiveness of fracture prevention treatments in the elderly.

Fleurence RL.

Int J Technol Assess Health Care. 2004 Spring;20(2):184-91.

PMID:
15209178

Supplemental Content

Loading ...
Support Center